Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 1.00 |
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 5/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | GRK6 | P43250 | 7/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780657 | 0.87 | NTRK1 (0.78) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4075967 | 0.87 | NTRK1 (0.78) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4073788 | 0.87 | NTRK1 (1.00) | NTRK1JAK2JAK3 | |
| SCHEMBL3338612 | 0.80 | NTRK1 (0.69) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL22535807 | 0.75 | NTRK1 (0.60) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL22535467 | 0.74 | NTRK1 (0.61) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4900453 | 0.74 | NTRK1 (0.79) | NTRK1JAK2JAK3 | |
| SCHEMBL4077514 | 0.74 | NTRK1 (0.79) | NTRK1JAK2JAK3 | |
| SCHEMBL22535416 | 0.73 | NTRK1 (0.69) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL4155679 | 0.73 | NTRK1 (1.00) | NTRK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005396-A1 | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain | P2RX3, DPYD, TYMP | NTRK1 3656/4885JAK2 1971/4885JAK3 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.